|
KMID : 0043320160390040539
|
|
Archives of Pharmacal Research
2016 Volume.39 No. 4 p.539 ~ p.546
|
|
|
Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats
|
|
Kim Dong-Wuk
Kim Young-Hun
Yousaf Abid Mehmood
Kim Dong-Shik
Kwon Taek-Kwan
Park Jung-Hee
Kim Yong-Il
Park Jae-Hyun
Jin Sung-Giu
Kim Kyung-Soo
Cho Kwan-Hyung
Li Dong Xun
Kim Jong-Oh
Yong Chul-Soon
Woo Jong-Soo
Choi Han-Gon
|
|
|
Abstract
|
|
|
|
To develop a montelukast sodium?loaded stable oral suspension bioequivalent to the commercial granules in rats, several montelukast sodium-loaded suspensions were prepared with a suspending agent, stabilizers and anti-aggregation agents, and their stabilities were investigated by visually observing the sedimentation phenomenon and determining the concentration of the degradation product. Moreover, dissolution and pharmacokinetic studies of the optimized formulation were examined in rats compared to commercial montelukast sodium-loaded granules. Avicel RC-591 (Avicel), a suspending agent, prevented the sedimentation of these suspensions at >2.496 (w/v) per cent composition. Amongst the stabilizers tested, fumaric acid provided the lowest concentration of montelukast sulphoxide (a degradation product) in these suspensions at 40 °C, demonstrating its excellent stabilizing activity. Furthermore, as an anti-aggregation agent, glycerin gave lower amounts of degradation product than those with poloxamer 407 and Tween 80. In particular, montelukast-loaded oral suspension, an aqueous suspension containing montelukast sodium/Avicel/fumaric acid/glycerin at a concentration of 312/2496/15.6/62.4 (mg/100 ml), and the commercial granules exhibited similar dissolution profiles in 0.5 % (w/v) aqueous solution of sodium lauryl sulphate. Moreover, the pharmacokinetics in rats provided by this suspension was comparable to that of the commercial granules, suggesting that they were bioequivalent. In addition, it was physically and chemically stable at 40 °C for at least 6 months. Thus, this montelukast sodium-loaded oral suspension, with bioequivalence to the commercial granules and excellent stability, could be a prospective dosage form for the treatment of asthma.
|
|
|
KEYWORD
|
|
|
Montelukast sodium, Oral suspension, Stability, Dissolution, Bioavailability
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|